Can-Fite Reports Positive Phase 2a Data for Namodenoson in Advanced Pancreatic Cancer

On April 30, 2026, Can-Fite BioPharma Ltd. announced positive clinical data from its Phase 2a open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma who have progressed on at least first-line therapy. The study met its primary endpoint of safety, demonstrating that the drug was well-tolerated in a heavily pretreated population with no new safety signals. Regarding secondary efficacy objectives, the trial showed preliminary evidence of clinical activity, including durable disease stabilization. Key findings revealed that stable disease was observed in over 30% of evaluable patients, and 35% of patients currently remain on therapy. Notably, one patient has extended treatment beyond 16 months. Namodenoson, a selective A3 adenosine receptor (A3AR) agonist, has already received Orphan Drug Designation from the FDA for pancreatic cancer. The company expects to release full efficacy analyses, including top-line results for progression-free survival (PFS) and overall survival (OS), in the coming months.